# Trimas Corp: Form 10-Q for the period ended Sep 30, 2021

- Company: [Trimas Corp](/companies/trs.md) (CIK 842633)
- Form: 10-Q
- Filed: 2021-10-28
- Accepted by EDGAR: Oct 28, 2021, 11:58 ET
- Period: 2021-09-30
- Accession: 0000842633-21-000085
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/842633/000084263321000085/trs-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/842633/000084263321000085/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $222.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $648.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-07-01 to 2021-09-30 | $164.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2021-01-01 to 2021-09-30 | $480.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-07-01 to 2021-09-30 | $58.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2021-01-01 to 2021-09-30 | $167.8m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2021-07-01 to 2021-09-30 | $27.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-01-01 to 2021-09-30 | $90.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | $30.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | $77.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-07-01 to 2021-09-30 | $3.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-01-01 to 2021-09-30 | $11.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | $7.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $10.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | $19.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | $44.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.45 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | $1.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | $0.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | $1.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 43,094,099 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 43,345,777 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | $77.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $29.9m | us-gaap:PaymentsToAcquireProductiveAssets |
| Share repurchases | 9 months, 2021-01-01 to 2021-09-30 | $18.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2021-09-30 | $137.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $443.4m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $1.26bn | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $138.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $643.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $614.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 80,487 characters.

*The following discussion and analysis of our financial condition contains forward-looking statements regarding industry outlook and our expectations regarding the performance of our business. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, the risks and uncertainties described under the heading "Forward-Looking Statements," at the beginning of this report. Our actual results may differ materially from those contained in or implied by any forward-looking statements. You should read the following discussion together with the Company's reports on file with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2020.*

### Introduction

We are a diversified manufacturer and provider of products for customers primarily in the consumer products, aerospace & defense and industrial markets. Our wide range of innovative products are designed and engineered to solve application-specific challenges that our customers face. We believe our businesses share important and distinguishing characteristics, including: well-recognized and leading brand names in the focused markets we serve; innovative product technologies and features; a high-degree of customer approved processes and qualifications; established distribution networks; relatively low ongoing capital investment requirements; strong cash flow conversion and long-term growth opportunities. While the majority of our revenue is in the United States, we manufacture and supply products globally to a wide range of companies. We report our business activity in three segments: Packaging, Aerospace and Specialty Products.

#### Key Factors Affecting Our Reported Results

Our businesses and results of operations depend upon general economic conditions. We serve customers in industries that are highly competitive, cyclical and that may be significantly impacted by changes in economic or geopolitical conditions.

In March 2020, the President of the United States declared the coronavirus ("COVID-19") outbreak a national emergency, as the World Health Organization determined it was a pandemic. In response to the COVID-19 pandemic, federal, provincial, state, county and local governments and public health organizations or authorities around the world implemented a variety of measures intended to control the spread of the virus, including quarantines, "shelter-in-place" or "stay-at-home" and similar orders, travel restrictions, business curtailments and closures, social distancing, personal hygiene requirements, and other measures.

We have been, and continue to be, focused on making sure the working environments for our employees are safe so our operations have the ability to deliver the products needed to support efforts to mitigate the COVID-19 pandemic. Nearly all of our manufacturing sites have been deemed essential operations and remained open during the COVID-19 pandemic, at varying levels of capacity and efficiency, experiencing only temporary shutdowns due to country-specific government mandates or for thorough cleaning as a result of suspected COVID-19 cases. The health of our employees, and the ability of our facilities to remain operational in the current regulated environment, will be critical to our future results of operations.

Our divisions were impacted in 2020 at differing levels and times, beginning with our Asian facilities and strategic supply network, both primarily in China, in late January, followed by our European (primarily Italy) and North American facilities in February and March. We implemented new work rules and processes, which promote social distancing and increased hygiene to ensure the safety of our employees, particularly at our production facilities. These measures, while not easily quantifiable, have increased the level of manufacturing inefficiencies due to elevated levels of absenteeism, resulting in less efficient production scheduling and, in certain cases, short-term idling of production. We expect that we will continue to operate with these protocols in place, which have impacted our results since early 2020.

Overall, our third quarter 2021 net sales increased approximately $23.0 million, or 11.5%, compared to third quarter 2020, primarily as a result of increased industrial demand in our Specialty Products segment, an acquisition in our Packaging segment and the impact of customers' stocking orders within our Aerospace segment. These increases were partially offset by a decline in sales of our Packaging segment's dispensing and closure products that are used in applications to fight the spread of germs, which sales reached record-high levels in third quarter 2020 when there was a significant spike in demand following the onset of the COVID-19 pandemic, but now have abated to what we believe is a new, and higher, normalized level.

The most significant drivers affecting our results of operations in third quarter 2021 compared with third quarter 2020, other than as directly impacted by demand level changes as a result of the COVID-19 pandemic, were goodwill and intangible asset impairment charges in third quarter 2020 in our Aerospace segment, the impact of our recent acquisitions and increases in the cost of certain raw materials.

During the third quarter of 2020, we determined there was a triggering event requiring an interim quantitative impairment assessment for goodwill and indefinite-lived intangible assets within our Aerospace segment. While third quarter operating results were below pre-pandemic projected levels, the larger driver of the triggering event was a significant reduction in the July 2020 financial projection update for the remainder of 2020 compared with prior projections, and uncertainty around the duration and magnitude of the impact of the COVID-19 pandemic on future financial results given the dependence of our Aerospace segment reporting units on future levels of air travel and new aircraft builds. We determined the carrying value of both of our Aerospace reporting units, as well as of certain trade names, exceeded the fair value, resulting in non-cash, pre-tax impairment charges of approximately $126.8 million to goodwill and $7.8 million to indefinite lived intangible assets.

In December 2020, we completed the acquisition of Affaba & Ferrari Srl ("Affaba & Ferrari"), which specializes in the design, development and manufacture of precision caps and closures for food & beverage and industrial product applications, for an aggregate amount of approximately $98.4 million, net of cash acquired. Affaba & Ferrari, which is reported in our Packaging segment, operates out of a highly automated manufacturing facility and support office located in Borgo San Giovanni, Italy. Affaba & Ferrari contributed approximately $11.4 million of net sales during third quarter 2021.

In first quarter 2021, we began experiencing an increase in material costs compared with 2020 levels, primarily for resin-based raw materials and components, as well as for certain types of steel. These material costs further increased during both the second and third quarters of 2021. We have escalator/de-escalator clauses in our commercial contracts with certain of our customers, or can modify prices based on market conditions, and we have been taking actions to recover the increased cost of raw materials. However, given the lag nature of the commercial pricing mechanisms, we have and will continue to experience net earnings pressure until resin costs begin to stabilize and/or decline for several consecutive months. We estimate that due to the lag in timing between incurring the cost increases and recovering via commercial actions, our operating profit was negatively impacted by approximately $3 million and $9 million in the three and nine months ended September 30, 2021, respectively, compared with 2020, primarily in our Packaging segment.

On a year-to-date basis, there were four additional significant drivers of year-over-year change in our results of operations.

In March 2021, we refinanced our long-term debt, issuing $400 million aggregate principal amount of 4.125% senior unsecured notes due April 15, 2029 ("2029 Senior Notes") at par value in a private placement under Rule 144A of the Securities Act of 1933, as amended, and amending our existing credit agreement ("Credit Agreement"), extending the maturity to March 2026. We used the proceeds from the 2029 Senior Notes offering to pay fees and expenses of approximately $5.1 million related to the offering and approximately $1.1 million related to amending the Credit Agreement. The remaining cash proceeds from the 2029 Senior Notes were used for general corporate purposes, including repaying all outstanding revolving credit facility borrowings and redeeming all of our outstanding senior notes due October 2025 ("2025 Senior Notes"), paying cash for the entire $300.0 million outstanding principal amount plus $7.3 million as a redemption premium. The $5.1 million of fees and expenses related to the 2029 Senior Notes were capitalized as debt issuance costs, while the $7.3 million redemption premium as well as approximately $3.0 million of unamortized debt issuance costs associated with the 2025 Senior Notes were expensed in the second quarter of 2021.

In the second quarter of 2020, we elected to change our accounting policy for asbestos-related defense costs from accruing for probable and reasonably estimable defense costs associated with known claims expected to settle to accruing for all future defense costs for both known and unknown claims, which we now believe can be reasonably estimated. This accounting change has been reflected as a change in accounting estimate effected by a change in accounting principle. We recorded a non-cash, pre-tax charge in second quarter 2020 for asbestos-related costs of approximately $23.4 million, which is included in selling, general and administrative expenses.

Beginning in second quarter 2020, we have been executing certain realignment actions in response to reductions in current and expected future end market demand following the onset of the COVID-19 pandemic. We recorded pre-tax facility consolidation and employee separation costs of approximately $2.7 million and $6.1 million, respectively, in the nine months ended September 30, 2021. In the nine months ended September 30, 2020, we recorded a pre-tax charge of approximately $13.2 million related to inventory reductions, primarily as a result of a strategic decision in our Arrow Engine division to streamline its product line offering. We also recorded charges of approximately $2.3 million related to certain production equipment removed from service given reduced demand levels, and employee separation costs of approximately $3.6 million.

In addition, our effective tax rate for the first nine months of 2021 was 19.2%, compared to 12.4% for the first nine months of 2020. The rate for the nine months ended September 30, 2021 is higher than in the prior year as the effective tax rate for the nine months ended September 30, 2020 was impacted by a decrease in profitability resulting from various realignment charges, expense for a change in the Company’s accounting policy for asbestos-related defense costs and impairment of goodwill and indefinite-lived intangible assets. The effective tax rate for the nine months ended September 30, 2021 was impacted by the recognition of approximately $3.0 million of deferred tax benefits in Italy, the majority of which related to a reduction in deferred tax liabilities in connection with certain tax incentives.

#### Additional Key Risks that May Affect Our Reported Results

We expect the COVID-19 pandemic will continue to impact us in the future at varying degrees. We expect the robust customer demand, compared with pre-pandemic demand levels, for our Packaging segment's dispensing pumps and closure products used in personal care and home care applications will continue, as we believe there is a positive secular trend focused on consumers' desire to stop the spread of germs and improve personal hygiene. We are actively collaborating with our customers and strategic supply partners to manage production capacity and supply chain availability as efficiently as possible. Industrial demand in North America was lower in 2020 compared to previous levels, and while demand levels significantly increased in both the second and third quarters of 2021, we are uncertain how and at what level demand will be impacted as governmental, travel or other restrictions are lifted, particularly in North America, where orders for our industrial cylinders, for example, are heavily influenced by the levels of construction and HVAC activity. We expect the aerospace market to continue to experience severe dislocation going forward, as except for the significant stocking orders for certain of our products received during 2021, our sales levels would be significantly lower than historical levels. With the current travel restrictions and significant drop in passenger miles, aircraft manufacturers have slowed production, and since second quarter 2020 we have experienced a significant drop in aerospace-related sales related to new commercial airplane builds compared to prior levels. We expect, except as favorably impacted by the customers' stocking orders in 2021, lower levels of sales and related production to continue for the foreseeable future.

We have executed significant realignment actions since the onset of the COVID-19 pandemic, primarily in our Aerospace and Specialty Products segments, and also in certain Packaging product areas where demand has fallen, such as in the quick service and restaurant applications, to protect against the uncertain end market demand. We will continue to assess further actions if required. However, as a result of the COVID-19 pandemic's impact on global economic activity, and the continued potential impact to our future results of operations, as well if there is an impact to TriMas' market capitalization, we may record additional cash and non-cash charges related to incremental realignment actions, as well as for uncollectible customer account balances, excess inventory and idle production equipment.

Despite the potential decline in future demand levels and results of operations as a result of the COVID-19 pandemic, at present, we believe our capital structure is in a solid position, even more so following our 2021 debt refinancing. We have ample cash and available liquidity under our revolving credit facility to meet our debt service obligations, capital expenditure requirements and other short-term and long-term obligations for the foreseeable future.

The extent of the COVID-19 pandemic's effect on our operational and financial performance will depend in large part on future

developments, which cannot be predicted with confidence at this time. Future developments include the duration, scope and severity of the COVID-19 pandemic, the actions taken to contain or mitigate its impact, timing of widespread vaccine availability, and the resumption of normalized global economic activity. Due to the inherent uncertainty of the unprecedented and rapidly evolving situation, we are unable to predict with any confidence the likely impact of the COVID-19 pandemic on our future operations.

Beyond the unique risks presented by the COVID-19 pandemic, other critical factors affecting our ability to succeed include: our ability to create organic growth through product development, cross-selling and extending product-line offerings, and our ability to quickly and cost-effectively introduce and successfully launch new products; our ability to acquire and integrate companies or products that supplement existing product lines, add new distribution channels or customers, expand our geographic coverage or enable better absorption of overhead costs; our ability to manage our cost structure more efficiently via supply base management, internal sourcing and/or purchasing of materials, selective outsourcing and/or purchasing of support functions, working capital management, and greater leverage of our administrative functions.

Our overall business does not experience significant seasonal fluctuation, other than our fourth quarter, which has tended to be the lowest net sales quarter of the year due to holiday shutdowns at certain customers or other customers deferring capital spending to the following year. Given the short-cycle nature of most of our businesses, we do not consider sales order backlog to be a material factor. A growing amount of our sales is derived from international sources, which exposes us to certain risks, including currency risks.

We are sensitive to price movements and availability of our raw materials supply. Our largest raw material purchases are for resins (such as polypropylene and polyethylene), steel, aluminum and other oil and metal-based purchased components. In addition to the factors affecting our third quarter 2021 results, there has been some volatility over the past two years as a direct and indirect result of foreign trade policy, where tariffs on certain of our commodity-based products sourced from Asia have been instituted, and certain North American suppliers have opportunistically increased their prices. We will continue to take actions to mitigate such increases, including implementing commercial pricing adjustments, resourcing to alternate suppliers and insourcing of previously sourced products to better leverage our global manufacturing footprint. Although we believe we are generally able to mitigate the impact of higher commodity costs over time, we may experience additional material costs and disruptions in supply in the future and may not be able to pass along higher costs to our customers in the form of price increases or otherwise mitigate the impacts to our operating results.

Although we have escalator/de-escalator clauses in commercial contracts with certain of our customers, or can modify prices based on market conditions to recover higher costs, our price increases generally lag the underlying material cost increase, and we cannot be assured of full cost recovery in the open market.

Our Arrow Engine business in our Specialty Products segment is sensitive to the demand for natural gas and crude oil in North America. For example, demand for engine, pump jack and compressor products are impacted by active oil and gas rig counts and wellhead investment activities. Separately, oil-based commodity costs are a significant driver of raw materials and purchased components used within our Packaging segment.

Each year, as a core tenet of the TriMas Business Model, our businesses target cost savings from Kaizen and continuous improvement initiatives in an effort to reduce, or otherwise offset, the impact of increased input and conversion costs through increased throughput and yield rates, with a goal of at least covering inflationary and market cost increases. In addition, we continuously review our operating cost structures to ensure alignment with current market demand.

We continue to evaluate alternatives to redeploy the cash generated by our businesses, one of which includes returning capital to our shareholders. In 2020, our Board of Directors increased the authorization of share repurchases to a cumulative amount of $250 million. During third quarter 2021, we purchased 129,866 shares of our outstanding common stock for approximately $4.0 million. As of September 30, 2021, we had approximately $143.5 million remaining under the repurchase authorization. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock, depending on market conditions and other factors.

### Segment Information and Supplemental Analysis

The following table summarizes financial information for our reportable segments for the three months ended September 30, 2021 and 2020 (dollars in thousands):

| Net Sales | Three months ended September 30, 2021 | As a Percentage of Net Sales | 2020 | As a Percentage of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| Packaging | $138,010 | 62.0% | $135,120 | 67.7% |
| Aerospace | 46,510 | 20.9% | 39,130 | 19.6% |
| Specialty Products | 37,900 | 17.0% | 25,210 | 12.6% |
| Total | $222,420 | 100.0% | $199,460 | 100.0% |
| **Gross Profit (Loss)** |  |  |  |  |
| Packaging | $39,410 | 28.6% | $40,240 | 29.8% |
| Aerospace | 10,150 | 21.8% | 6,930 | 17.7% |
| Specialty Products | 8,880 | 23.4% | 4,760 | 18.9% |
| Total | $58,440 | 26.3% | $51,930 | 26.0% |
| **Selling, General and Administrative Expenses** |  |  |  |  |
| Packaging | $12,070 | 8.7% | $12,220 | 9.0% |
| Aerospace | 6,160 | 13.2% | 5,840 | 14.9% |
| Specialty Products | 2,230 | 5.9% | 1,370 | 5.4% |
| Corporate | 7,160 | N/A | 6,220 | N/A |
| **Total** | $27,620 | 12.4% | $25,650 | 12.9% |
| **Operating Profit (Loss)** |  |  |  |  |
| Packaging | $27,340 | 19.8% | $28,020 | 20.7% |
| Aerospace | 3,980 | 8.6% | (133,500) | (341.2)% |
| Specialty Products | 6,660 | 17.6% | 3,380 | 13.4% |
| Corporate | (7,160) | N/A | (6,220) | N/A |
| Total | $30,820 | 13.9% | $(108,320) | (54.3)% |
| **Depreciation** |  |  |  |  |
| Packaging | $5,280 | 3.8% | $4,490 | 3.3% |
| Aerospace | 1,670 | 3.6% | 1,640 | 4.2% |
| Specialty Products | 930 | 2.5% | 770 | 3.1% |
| Corporate | 30 | N/A | 30 | N/A |
| Total | $7,910 | 3.6% | $6,930 | 3.5% |
| **Amortization** |  |  |  |  |
| Packaging | $2,380 | 1.7% | $2,320 | 1.7% |
| Aerospace | 2,870 | 6.2% | 2,880 | 7.4% |
| Specialty Products | 120 | 0.3% | 110 | 0.4% |
| Corporate | — | N/A | — | N/A |
| Total | $5,370 | 2.4% | $5,310 | 2.7% |

30

The following table summarizes financial information for our reportable segments for the nine months ended September 30, 2021 and 2020 (dollars in thousands):

| Net Sales | Nine months ended September 30, 2021 | As a Percentage of Net Sales | 2020 | As a Percentage of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| Packaging | 409,730 | 63.2% | 364,000 | 62.6% |
| Aerospace | 135,680 | 20.9% | 130,660 | 22.5% |
| Specialty Products | 102,730 | 15.8% | 87,140 | 15.0% |
| Total | $648,140 | 100.0% | $581,800 | 100.0% |
| **Gross Profit** |  |  |  |  |
| Packaging | 113,770 | 27.8% | 106,770 | 29.3% |
| Aerospace | 30,430 | 22.4% | 21,510 | 16.5% |
| Specialty Products | 23,600 | 23.0% | 7,250 | 8.3% |
| Total | $167,800 | 25.9% | $135,530 | 23.3% |
| **Selling, General and Administrative Expenses** |  |  |  |  |
| Packaging | 37,280 | 9.1% | 36,430 | 10.0% |
| Aerospace | 19,820 | 14.6% | 19,550 | 15.0% |
| Specialty Products | 6,420 | 6.2% | 6,370 | 7.3% |
| Corporate | 26,780 | N/A | 45,220 | N/A |
| Total | $90,300 | 13.9% | $107,570 | 18.5% |
| **Operating Profit (Loss)** |  |  |  |  |
| Packaging | 76,490 | 18.7% | 70,340 | 19.3% |
| Aerospace | 10,600 | 7.8% | (132,630) | (101.5)% |
| Specialty Products | 17,190 | 16.7% | 870 | 1.0% |
| Corporate | (26,780) | N/A | (45,220) | N/A |
| Total | $77,500 | 12.0% | $(106,640) | (18.3)% |
| **Depreciation** |  |  |  |  |
| Packaging | 15,680 | 3.8% | 13,630 | 3.7% |
| Aerospace | 5,260 | 3.9% | 5,400 | 4.1% |
| Specialty Products | 2,710 | 2.6% | 2,570 | 2.9% |
| Corporate | 90 | N/A | 100 | N/A |
| Total | $23,740 | 3.7% | $21,700 | 3.7% |
| **Amortization** |  |  |  |  |
| Packaging | 7,180 | 1.8% | 6,970 | 1.9% |
| Aerospace | 8,630 | 6.4% | 8,140 | 6.2% |
| Specialty Products | 340 | 0.3% | 350 | 0.4% |
| Corporate | — | N/A | — | N/A |
| Total | $16,150 | 2.5% | $15,460 | 2.7% |

#### Results of Operations

The principal factors impacting us during the three months ended September 30, 2021, compared with the three months ended September 30, 2020, were:

- the impact on global business activity of the COVID-19 pandemic;
- approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges in third quarter 2020;
- the impact of our recent acquisitions, primarily Affaba & Ferrari, in December 2020; and
- the impact of material cost increases, primarily resin-related.

### Three Months Ended September 30, 2021 Compared with Three Months Ended September 30, 2020

Overall, net sales increased approximately $23.0 million, or 11.5%, to $222.4 million for the three months ended September 30, 2021, as compared with $199.5 million in the three months ended September 30, 2020. The acquisition of Affaba and Ferrari added approximately $11.4 million of sales. Organic sales, excluding the impact of currency exchange and acquisitions, increased approximately $9.7 million, as increases in our Aerospace and Specialty Products segments were partially offset by the expected decline in organic sales in our Packaging segment as the high demand levels for products that help fight the spread of germs decreased compared with the record-high levels in the prior year. In addition, net sales increased by approximately $1.9 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of a weakening U.S. dollar relative to foreign currencies, as compared to third quarter 2020.

Gross profit margin (gross profit as a percentage of sales) approximated 26.3% and 26.0% for the three months ended September 30, 2021 and 2020, respectively. Gross profit margin increased as a result of an approximate $2.0 million charge within our Aerospace segment related to an updated estimate of a pre-acquisition contingent liability taken in the third quarter of 2020 that did not repeat in 2021, as well as due to leveraging our realignment actions taken during 2020, primarily in our Specialty Products segment. These margin improvements were partially offset by increased material costs, primarily in our Packaging segment, an overall less favorable product sales mix, and due to production inefficiencies, primarily in our Aerospace segment, driven by the COVID-19 pandemic.

Operating profit (loss) margin (operating profit as a percentage of sales) approximated 13.9% and (54.3)% for the three months ended September 30, 2021 and 2020, respectively. Operating profit (loss) increased approximately $139.1 million to an operating profit of approximately $30.8 million in the three months ended September 30, 2021, from an operating loss of approximately $108.3 million for the three months ended September 30, 2020, primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges as well as the impact of the $2.0 million pre-acquisition contingent liability charge within our Aerospace segment, all of which were recorded during the third quarter of 2020 and did not repeat in 2021. Operating profit and margin further increased due to higher sales levels and favorable currency exchange, which were partially offset by material cost increases and higher production inefficiencies.

Interest expense remained relatively flat at approximately $3.4 million, for the three months ended September 30, 2021 compared to approximately $3.5 million for the three months ended September 30, 2020.

Other expense decreased approximately $0.7 million to approximately $0.5 million for the three months ended September 30, 2021, as compared to approximately $1.2 million for the three months ended September 30, 2020, primarily due to a decrease in losses on transactions denominated in foreign currencies.

The effective income tax rate for the three months ended September 30, 2021 and 2020 was 27.0% and 10.7%, respectively. We recorded income tax expense of approximately $7.3 million for the three months ended September 30, 2021 as compared to an income tax benefit of approximately $12.1 million for the three months ended September 30, 2020. The rate for the three months ended September 30, 2021 is higher than in the prior year primarily due to goodwill and intangible asset impairment charges, a portion of which was not tax deductible. The tax benefit associated with the goodwill and intangible asset impairment charges was treated as a discrete item in determining tax expense for the three months ended September 30, 2020.

Net income (loss) increased approximately $120.5 million, to net income of $19.6 million for the three months ended September 30, 2021, as compared to a net loss of $100.9 million for the three months ended September 30, 2020. The increase was primarily the result of an increase in operating profit (loss) of approximately $139.1 million and a decrease in other expense of approximately $0.7 million, partially offset by an increase in income tax expense of approximately $19.4 million.

See below for a discussion of operating results by segment.

***Packaging.*** Net sales increased approximately $2.9 million, or 2.1%, to $138.0 million in the three months ended September 30, 2021, as compared to $135.1 million in the three months ended September 30, 2020. Affaba & Ferrari, acquired in December 2020, contributed approximately $11.4 million of sales in the third quarter of 2021. Sales of products used in food and beverage markets increased by approximately $6.4 million, primarily due to strong demand for closures, dispensers and flexible packaging as the hospitality sector began to rebound from prior COVID-19 pandemic-related shutdowns. Sales of products used in industrial markets increased by approximately $4.7 million, primarily as a result of higher demand for closure products in North America. Sales of beauty and personal care dispensing products used in applications that help fight the spread of germs decreased by approximately $21.0 million, as demand has abated for these products from the peak levels in 2020 as a result of the COVID-19 pandemic, to what we believe is a new, and higher, normalized level. Net sales also increased by approximately $1.9 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies, as compared to third quarter 2020.

Gross profit decreased approximately $0.8 million to $39.4 million, or 28.6% of sales, in the three months ended September 30, 2021, as compared to $40.2 million, or 29.8% of sales, in the three months ended September 30, 2020. Gross profit was impacted in third quarter 2021 by approximately $3 million of higher year-over-year material costs (primarily resin) than were recovered via sales price increases. This decrease was mostly offset by a more favorable product sales mix, with higher margin industrial and food and beverage products comprising a greater percentage of total sales, as well as a result of approximately $0.7 million of currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies.

Selling, general and administrative expenses decreased approximately $0.2 million to $12.1 million, or 8.7% of sales, in the three months ended September 30, 2021, as compared to $12.2 million, or 9.0% of sales, in the three months ended September 30, 2020, as the impact of lower employee related costs and third party expenses was mostly offset by higher ongoing selling, general and administrative costs associated with our acquisition of Affaba & Ferrari.

Operating profit decreased approximately $0.7 million to $27.3 million, or 19.8% of sales, in the three months ended September 30, 2021, as compared to $28.0 million, or 20.7% of sales, in the three months ended September 30, 2020, as the impact of material cost increases and slightly higher selling, general and administrative expenses more than offset a more favorable product sales mix and the impact of currency exchange.

***Aerospace.*** Net sales for the three months ended September 30, 2021 increased approximately $7.4 million, or 18.9%, to $46.5 million, as compared to $39.1 million in the three months ended September 30, 2020. Sales of our fasteners products increased by approximately $5.6 million, as the impact of customers' stocking orders for specialized fasteners of approximately $6.9 million was partially offset by a decline in overall market-related demand due to the COVID-19 pandemic. Sales of our engineered components increased by approximately $1.8 million, primarily due to timing of end market demand.

Gross profit increased approximately $3.2 million to $10.2 million, or 21.8% of sales, in the three months ended September 30, 2021, from $6.9 million, or 17.7% of sales, in the three months ended September 30, 2020, due to the higher sales levels, as well as to an approximate $2.0 million charge related to an updated estimate of a pre-acquisition contingent liability taken in the third quarter of 2020 that did not repeat in 2021. These increases were partially offset by production inefficiencies driven by the effects of the COVID-19 pandemic.

Selling, general and administrative expenses increased approximately $0.3 million to $6.2 million, or 13.2% of sales, in the three months ended September 30, 2021, as compared to $5.8 million, or 14.9% of sales, in the three months ended September 30, 2020, as we minimized incremental spending despite higher sales levels.

Operating profit (loss) increased approximately $137.5 million to an operating profit of $4.0 million, or 8.6% of sales, in the three months ended September 30, 2021, as compared to an operating loss of $133.5 million, or 341.2% of sales, in the three months ended September 30, 2020, primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges as well as the impact of the updated pre-acquisition contingent liability charge, all of which were recorded during the third quarter of 2020 and did not repeat in 2021. These improvements, plus the impact of higher sales levels, were partially offset by production inefficiencies and higher selling, general and administrative expenses.

***Specialty Products.*** Net sales for the three months ended September 30, 2021 increased approximately $12.7 million, or 50.3%, to $37.9 million, as compared to $25.2 million in the three months ended September 30, 2020. Sales of our cylinder products increased approximately $9.3 million, due to higher demand for steel cylinders in North America as industrial activity continues to increase following the previous lower levels a year ago as a result of the COVID-19 pandemic. Sales of engines, compressors and related parts used in upstream oil and gas applications increased by approximately $3.4 million, primarily as a result of higher oil-field activity in North America.

Gross profit increased approximately $4.1 million to $8.9 million, or 23.4% of sales, in the three months ended September 30, 2021, as compared to $4.8 million, or 18.9% of sales, in the three months ended September 30, 2020. Gross profit increased in the third quarter of 2021 due to higher sales levels, while margins further improved due to favorable product sales mix and leveraging previous realignment actions.

Selling, general and administrative expenses increased approximately $0.9 million to $2.2 million, or 5.9% of sales, in the three months ended September 30, 2021, as compared to $1.4 million, or 5.4% of sales, in the three months ended September 30, 2020, primarily due to higher employment and spending levels in support of the increase in sales levels.

Operating profit increased approximately $3.3 million to $6.7 million, or 17.6% of sales, in the three months ended September 30, 2021, as compared to $3.4 million, or 13.4% of sales, in the three months ended September 30, 2020, primarily due to increased sales levels, a more favorable product sales mix and leveraging previous realignment actions.

***Corporate.*** Corporate expenses consist of the following (dollars in millions):

|  | Three months ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Corporate operating expenses | $5.5 | $5.1 |
| Non-cash stock compensation | 1.6 | 0.9 |
| Legacy expenses | 0.1 | 0.2 |
| Corporate expenses | $7.2 | $6.2 |

Corporate expenses increased approximately $0.9 million to approximately $7.2 million for the three months ended September 30, 2021, from approximately $6.2 million for the three months ended September 30, 2020, primarily as a result of an increase in non-cash stock compensation due to timing and higher estimated attainment of existing awards, as well as due to higher Corporate operating expenses.

### Nine Months Ended September 30, 2021 Compared with Nine Months Ended September 30, 2020

Overall, net sales increased approximately $66.3 million, or 11.4%, to $648.1 million for the nine months ended September 30, 2021, as compared with $581.8 million in the nine months ended September 30, 2020, primarily as a result of acquisitions, which added approximately $39.0 million of sales. Organic sales, excluding the impact of currency exchange and acquisitions, increased in each of our three segments, growing a total of approximately $18.1 million. Organic sales in our Specialty Products segment increased approximately $15.6 million as a result of increased industrial and oil-field activity. Organic sales in our Packaging segment increased approximately $1.8 million, as increases in products used in food and beverage, industrial and other applications were mostly offset by a decrease in sales of dispensing products used in beauty and personal care and home care applications that help fight the spread of germs. Organic sales in our Aerospace segment increased approximately $0.7 million, as sales for customers' stocking orders were mostly offset by a decline in sales resulting from the impact from the COVID-19 pandemic on the overall aerospace industry. Net sales increased by approximately $9.3 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies.

Gross profit margin (gross profit as a percentage of sales) approximated 25.9% and 23.3% for the nine months ended September 30, 2021 and 2020, respectively. Gross profit margin increased primarily due to the impact of lower realignment, contingent liability and purchase accounting charges of approximately $13.1 million, $2.0 million and $2.0 million, respectively, in the first nine months of 2021 than the first nine months of 2020. These increases, plus a more favorable product sales mix and leveraging of our prior realignment actions in our Specialty Products segment were partially offset by higher material costs (primarily resin) in our Packaging segment and production inefficiencies within our Aerospace segment.

Operating profit (loss) margin (operating profit as a percentage of sales) approximated 12.0% and (18.3)% for the nine months ended September 30, 2021 and 2020, respectively. Operating profit increased approximately $184.1 million, to $77.5 million for the nine months ended September 30, 2021, compared to $106.6 million for the nine months ended September 30, 2020, primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges as well as the impact of the $2.0 million pre-acquisition contingent liability charge within our Aerospace segment, all of which were recorded during the third quarter of 2020 and did not repeat in 2021. Operating profit and margin further increased due to higher sales levels and lower realignment and purchase accounting costs than in 2020. These increases were partially offset by higher material costs (primarily resin) in our Packaging segment and production inefficiencies within our Aerospace segment.

Interest expense decreased approximately $0.2 million, to $11.1 million, for the nine months ended September 30, 2021, as compared to $11.3 million for the nine months ended September 30, 2020 as a lower effective interest rate more than offset an increase in our weighted average borrowings.

We incurred approximately $10.5 million of debt financing and related expense for the nine months ended September 30, 2021, of which approximately $10.3 million was related to expenses incurred associated with the redemption of our 2025 Senior Notes and approximately $0.2 million related to the write-off of previously capitalized deferred financing fees associated with our Credit Agreement.

Other expense increased approximately $0.7 million, to $0.8 million for the nine months ended September 30, 2021, from $0.2 million for the nine months ended September 30, 2020, primarily due to a year-over-year increase in losses on transactions denominated in foreign currencies.

The effective income tax rate for the nine months ended September 30, 2021 and 2020 was 19.2% and 12.4%, respectively. We recorded tax expense of approximately $10.6 million for the nine months ended September 30, 2021 as compared to a tax benefit of approximately $14.6 million for the nine months ended September 30, 2020. The rate for the nine months ended September 30, 2021 is higher than in the prior year as the effective tax rate for the nine months ended September 30, 2020 was impacted by a decrease in profitability resulting from various realignment charges, expense for a change in the Company’s accounting policy for asbestos-related defense costs and impairment of goodwill and indefinite-lived intangible assets. The effective tax rate for the nine months ended September 30, 2021 was impacted by the recognition of approximately $3.0 million of deferred tax benefits in Italy, the majority of which related to a reduction in deferred tax liabilities in connection with certain tax incentives.

Net income increased by approximately $147.9 million, to net income of $44.5 million for the nine months ended September 30, 2021, compared to a net loss of $103.5 million for the nine months ended September 30, 2020. The increase was primarily the result of an increase in operating profit of approximately $184.1 million and a decrease in interest expense of $0.2 million, partially offset by debt financing and related expenses of approximately $10.5 million, an increase in income tax expense of approximately $25.2 million and an increase in other expense of approximately $0.7 million.

See below for a discussion of operating results by segment.

***Packaging.*** Net sales increased approximately $45.7 million, or 12.6%, to $409.7 million in the nine months ended September 30, 2021, as compared to $364.0 million in the nine months ended September 30, 2020. Acquisition-related sales growth was approximately $34.7 million, comprised of $29.4 million of sales from our December 2020 acquisition of Affaba & Ferrari and $5.3 million resulting from the January through March 2021 sales of our April 2020 acquisition of Rapak. Sales of products used in food and beverage markets increased by approximately $8.4 million, primarily due to strong demand for caps, closures and flexible packaging as the hospitality sector began to rebound from prior COVID-19 pandemic-related shutdowns. Sales of products used in industrial markets increased by approximately $7.9 million, primarily as a result of higher demand for closure products in North America. Sales of dispensing products used in beauty and personal care as well as home care applications that help fight the spread of germs decreased by approximately $18.6 million, as demand has abated for these products from the peak levels in 2020 as a result of the COVID-19 pandemic. Net sales also increased by approximately $9.3 million due to currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies.

Packaging's gross profit increased approximately $7.0 million to $113.8 million, or 27.8% of sales, in the nine months ended September 30, 2021, as compared to $106.8 million, or 29.3% of sales, in the nine months ended September 30, 2020, primarily due to the higher sales levels, plus approximately $3.2 million of currency exchange, as our reported results in U.S. dollars were favorably impacted as a result of the weakening U.S. dollar relative to foreign currencies. Gross profit margin also increased as a result of a more favorable product sales mix, as higher margin industrial and food and beverage products comprised a larger percentage of total sales. These increases were partially offset by approximately $9 million of higher material costs (primarily resin) than were recovered via sales price increases in the nine months ended September 30, 2021. In addition, during the first three quarters of 2021, we recognized approximately $1.6 million of realignment costs primarily related to the closure of our Union City, California manufacturing facility and consolidation into our Indianapolis, Indiana and Woodridge, Illinois facilities as compared to $0.9 million of realignment costs in the comparable period in 2020, primarily related to the disposal of certain equipment removed from service.

Packaging's selling, general and administrative expenses increased approximately $0.9 million to $37.3 million, or 9.1% of sales, in the nine months ended September 30, 2021, as compared to $36.4 million, or 10.0% of sales, in the nine months ended September 30, 2020, primarily due to higher ongoing selling, general and administrative costs associated with our acquisitions, partially offset by approximately $1.4 million in charges associated with realignment actions in the first nine months of 2020, primarily for severance, that did not repeat in 2021.

Packaging's operating profit increased approximately $6.2 million to $76.5 million, or 18.7% of sales, in the nine months ended September 30, 2021, as compared to $70.3 million, or 19.3% of sales, in the nine months ended September 30, 2020, primarily due to higher sales levels, a more favorable product sales mix and favorable currency exchange, which were partially offset by the impact of higher material costs, incremental realignment charges, and higher selling, general and administrative expenses.

***Aerospace.*** Net sales for the nine months ended September 30, 2021 increased approximately $5.0 million, or 3.8%, to $135.7 million, as compared to $130.7 million in the nine months ended September 30, 2020. RSA, acquired in February 2020, added approximately $4.3 million of sales for January and February 2021. Sales of our fastener products increased approximately $1.3 million, as approximately $20.8 million of sales of customers' stocking orders for specialized fasteners in the first nine months of 2021 were mostly offset by lower year-over-year sales resulting from current and expected future reduced air travel due to the COVID-19 pandemic. Sales of our engineered components products declined by approximately $0.6 million.

Gross profit within Aerospace increased approximately $8.9 million to $30.4 million, or 22.4% of sales, in the nine months ended September 30, 2021, from $21.5 million, or 16.5% of sales, in the nine months ended September 30, 2020, primarily due to charges recorded in the first nine months of 2020 that did not repeat in the first nine months of 2021. First, we recorded approximately $5.0 million lower realignment charges in the first nine months of 2021 compared with the first nine months of 2020, which were principally related to inventory reductions and facility consolidations in response to the COVID-19 pandemic. In addition, in the first nine months of 2020, we recorded a $2.0 million charge related to an updated estimate of a pre-acquisition contingent liability, as well as an approximate $2.0 million purchase accounting non-cash charge related to the step-up of RSA's inventory to fair value and subsequent amortization, each of which did not repeat in 2021. In addition to the impact of these charges, gross profit further increased due to the impact of higher sales. All of these factors were partially offset by lower absorption of fixed costs and production inefficiencies during 2021 driven by the COVID-19 pandemic.

Selling, general and administrative expenses increased approximately $0.3 million to $19.8 million, or 14.6% of sales, in the nine months ended September 30, 2021, as compared to $19.6 million, or 15.0% of sales, in the nine months ended September 30, 2020, primarily due to the impact of higher ongoing selling, general and administrative costs associated with our acquisition of RSA.

Operating profit (loss) within Aerospace increased approximately $143.2 million to an operating profit of $10.6 million, or 7.8% of sales, in the nine months ended September 30, 2021, as compared to an operating loss of $132.6 million, or (101.5)% of sales, in the nine months ended September 30, 2020, primarily due to approximately $134.6 million of goodwill and indefinite-lived intangible asset impairment charges during the third quarter of 2020. Operating profit also improved due to lower realignment and other charges recorded in the first nine months of 2020 that did not repeat in 2021, partially offset by production inefficiencies and higher selling, general and administrative expenses.

***Specialty Products.*** Net sales for the nine months ended September 30, 2021 increased approximately $15.6 million, or 17.9%, to $102.7 million, as compared to $87.1 million in the nine months ended September 30, 2020. Sales of our cylinder products increased approximately $11.2 million, due to higher demand for steel cylinders in North America as industrial activity is now increasing following the previous lower levels in 2020 as a result of the COVID-19 pandemic. Sales of engines, compressors and related parts used in upstream oil and gas applications increased by approximately $4.4 million, primarily as a result of higher oil-field activity in North America. Our sales in the first nine months of 2020 included approximately $0.7 million related to the liquidation of non-core inventory following our strategic decision to streamline Arrow Engine's product line offering.

Gross profit within Specialty Products increased approximately $16.4 million to $23.6 million, or 23.0% of sales, in the nine months ended September 30, 2021, as compared to $7.3 million, or 8.3% of sales, in the nine months ended September 30, 2020. During the nine months ended September 30, 2020, we executed certain realignment actions in response to reduced end market demand as a result of the COVID-19 pandemic, resulting in approximately $9.0 million of non-cash charges, primarily related to Arrow Engine streamlining its product line offering and liquidating the non-core inventory, which did not repeat in 2021. In addition, gross profit increased in the nine months ended September 30, 2021 due to higher sales levels, while margins further improved due to favorable product sales mix and leveraging the previous realignment actions.

Selling, general and administrative expenses within Specialty Products increased approximately $0.1 million to $6.4 million, or 6.2% of sales, in the nine months ended September 30, 2021, as compared to $6.4 million, or 7.3% of sales, in the nine months ended September 30, 2020. Our 2021 selling, general and administrative expenses have increased primarily due to higher employment and spending levels aligned with the increase in sales levels. We incurred selling, general and administrative realignment expenses of approximately $0.7 million in the nine months ended September 30, 2020 related to severance that did not repeat in 2021.

Operating profit within Specialty Products increased approximately $16.3 million to $17.2 million, or 16.7% of sales, in the nine months ended September 30, 2021, as compared to $0.9 million, or 1.0% of sales, in the nine months ended September 30, 2020, primarily due to the impact of 2020 realignment costs that did not repeat in 2021, as well as higher sales and related profit conversion leveraging the 2020 realignment actions without the need to add incremental fixed costs.

***Corporate.*** Corporate expenses, net consist of the following (dollars in millions):

|  | Nine months ended September 30, 2021 | 2020 |
| --- | ---: | ---: |
| Corporate operating expenses | $18.5 | $16.1 |
| Non-cash stock compensation | 7.3 | 5.6 |
| Legacy expenses | 1.0 | 23.5 |
| Corporate expenses | $26.8 | $45.2 |

Corporate expenses decreased approximately $18.4 million to $26.8 million for the nine months ended September 30, 2021, from $45.2 million for the nine months ended September 30, 2020, primarily as a result of the $23.4 million non-cash charge recorded in 2020 due to the change of our accounting policy for asbestos-related defense costs. Corporate operating expenses increased primarily as a result of realignment charges related to the corporate office legal and finance groups in the nine months ended September 30, 2021.

### Liquidity and Capital Resources

#### Cash Flows

Cash flows provided by operating activities were approximately $77.7 million for the nine months ended September 30, 2021, as compared to approximately $79.1 million for the nine months ended September 30, 2020. Significant changes in cash flows provided by operating activities and the reasons for such changes were as follows:

- For the nine months ended September 30, 2021, the Company generated approximately $110.2 million of cash, based on the reported net income of approximately $44.5 million and after considering the effects of non-cash items related to depreciation, amortization, loss on dispositions of assets, changes in deferred income taxes, debt financing and related expenses, stock-based compensation and other operating activities. For the nine months ended September 30, 2020, the Company generated approximately $82.7 million in cash flows based on the reported net loss of approximately $103.5 million and after considering the effects of similar non-cash items, the asbestos-related change in liability estimate and the impairment of goodwill and indefinite-lived intangible assets.
- Increases in accounts receivable resulted in a use of cash of approximately $23.3 million and $6.2 million for the nine months ended September 30, 2021 and 2020, respectively. The increased use of cash for each of the nine month periods is due primarily to the timing of sales and collection of cash related thereto within the periods. Days sales outstanding of receivables increased two days through the nine months ended September 30, 2021, and remained relatively consistent through the nine months ended September 30, 2020.
- We increased our investment in inventory by approximately $5.9 million for the nine months ended September 30, 2021 and decreased our investment in inventory by approximately $4.5 million for the nine months ended September 30, 2020. Our days sales in inventory decreased by approximately ten days in 2021 through solid inventory management even as our 2021 net sales increased above 2020 levels. Our days sales in inventory decreased by approximately 12 days through the nine months ended September 30, 2020, primarily as a result of of the strategic decision in our Arrow Engine division to streamline its product line offering.
- Increases in prepaid expenses and other assets resulted in a use of cash of approximately $3.8 million for the nine months ended September 30, 2021. Decreases in prepaid expenses and other assets resulted in a source of cash of approximately $5.5 million for the nine months ended September 30, 2020. These changes were primarily a result of the timing of payments made for income taxes and certain operating expenses.
- An increase in accounts payable and accrued liabilities resulted in a source of cash of approximately $0.5 million for the nine months ended September 30, 2021, while a decrease in accounts payable and accrued liabilities resulted in a use of cash of approximately $7.4 million for the nine months ended September 30, 2020. Days accounts payable on hand remained consistent in 2021, while days payables decreased by six days in 2020, primarily as we paid certain key Packaging vendors more quickly in 2020 to ensure our orders remained a top priority for them given our robust demand levels and minimal available capacity in the marketplace.

Net cash used for investing activities for the nine months ended September 30, 2021 and 2020 was approximately $29.7 million and $110.9 million, respectively. During the first nine months of 2021, we invested approximately $29.9 million in capital expenditures, as we continued our investment in growth, capacity and productivity-related capital projects. During the first nine months of 2020, we invested approximately $17.7 million in capital expenditures and paid approximately $95.2 million, net of cash acquired, to acquire RSA and Rapak. We also received proceeds from disposition of business, property and equipment of approximately $1.9 million in the first nine months of 2020.

Net cash provided by financing activities for the nine months ended September 30, 2021 was approximately $15.0 million, while net cash used for financing activities was approximately $40.9 million for the nine months ended September 30, 2020. During the first nine months of 2021, we issued $400.0 million principal amount of senior notes, made net repayments of approximately $48.6 million on our revolving credit facilities, and redeemed $300.0 million principal amount of senior notes. In connection with refinancing our long-term debt, we paid approximately $13.6 million of debt financing fees and redemption premium. We also purchased approximately $18.2 million of outstanding common stock and used a net cash amount of approximately $4.7 million related to our stock compensation arrangements. During the first nine months of 2020, we made net repayments of approximately $2.3 million, on our revolving credit facilities. We also purchased approximately $36.1 million of outstanding common stock and used a net cash amount of approximately $2.6 million related to our stock compensation arrangements.

#### Our Debt and Other Commitments

In March 2021, we issued the 2029 Senior Notes in a private placement under Rule 144A of the Securities Act of 1933, as amended. We used the proceeds from the 2029 Senior Notes offering to pay fees and expenses of approximately $5.1 million related to the offering and pay fees and expenses of $1.1 million related to amending our Credit Agreement. In connection with the issuance, during the second quarter of 2021, we completed the redemption of our 2025 Senior Notes, paying $300.0 million to retire the outstanding principal amount plus $7.3 million as a redemption premium. The remaining cash proceeds from the 2029 Senior Notes were used for general corporate purposes, including repaying all outstanding revolving credit facility borrowings. The $5.1 million of fees and expenses related to the 2029 Senior Notes were capitalized as debt issuance costs, while the $7.3 million redemption premium as well as approximately $3.0 million of unamortized debt issuance costs associated with the 2025 Senior Notes were recorded as expense within debt financing and related expenses in the accompanying statement of operations in the nine months ended September 30, 2021.

The 2029 Senior Notes accrue interest at a rate of 4.125% per annum, payable semi-annually in arrears on April 15 and October 15, commencing October 15, 2021. The payment of principal and interest is jointly and severally guaranteed, on a senior unsecured basis, by certain subsidiaries of the Company (each a "Guarantor" and collectively the "Guarantors"). The 2029 Senior Notes are *pari passu* in right of payment with all existing and future senior indebtedness and effectively subordinated to all existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness.

Prior to April 15, 2024, we may redeem up to 40% of the principal amount of the 2029 Senior Notes at a redemption price of 104.125% of the principal amount, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of one or more equity offerings provided that each such redemption occurs within 90 days of the date of closing of each such equity offering. In addition, prior to April 15, 2024, we may redeem all or part of the 2029 Senior Notes at a redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus a "make whole" premium.

For the nine months ended September 30, 2021, our consolidated subsidiaries that do not guarantee the 2029 Senior Notes represented approximately 28% of the total of guarantor and non-guarantor net sales, treating each as a consolidated group and excluding intercompany transactions between guarantor and non-guarantor subsidiaries. In addition, our non-guarantor subsidiaries represented approximately 42% and 49% of the total guarantor and non-guarantor assets and liabilities, respectively, as of September 30, 2021, treating the guarantor and non-guarantor subsidiaries each as a consolidated group.

In March 2021, we amended our Credit Agreement in connection with the issuance of the 2029 Senior Notes to extend the maturity date. We incurred fees and expenses of approximately $1.1 million related to the amendment, all of which were capitalized as debt issuance costs. We also recorded approximately $0.2 million of non-cash expense related to the write-off of previously capitalized deferred financing fees. The Credit Agreement consists of a $300.0 million senior secured revolving credit facility, which permits borrowings denominated in specific foreign currencies, subject to a $125.0 million sub limit, maturing on March 29, 2026 and is subject to interest at London Interbank Offered Rate ("LIBOR") plus 1.50%. The interest rate spread is based upon the leverage ratio, as defined, as of the most recent determination date.

The Credit Agreement provides for incremental revolving credit commitments in an amount not to exceed the greater of $200.0 million and an amount such that, after giving effect to such incremental commitments and the incurrence of any other indebtedness substantially simultaneously with the making of such commitments, the senior secured net leverage ratio, as defined in the Credit Agreement, is no greater than 3.00 to 1.00. The terms and conditions of any incremental revolving credit facility commitments must be no more favorable than the existing credit facility.

Amounts drawn under our revolving credit facility fluctuate daily based upon our working capital and other ordinary course needs. Availability under our revolving credit facility depends upon, among other things, compliance with our Credit Agreement's financial covenants. Our Credit Agreement contains various negative and affirmative covenants and other requirements affecting us and our subsidiaries, including the ability to, subject to certain exceptions and limitations, incur debt, liens, mergers, investments, loans, advances, guarantee obligations, acquisitions, asset dispositions, sale-leaseback transactions, hedging agreements, dividends and other restricted payments, transactions with affiliates, restrictive agreements and amendments to charters, bylaws, and other material documents. The terms of our Credit Agreement require us and our subsidiaries to meet certain restrictive financial covenants and ratios computed quarterly, including a maximum total net leverage ratio (total consolidated indebtedness plus outstanding amounts under the accounts receivable securitization facility, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined), a maximum senior secured net leverage ratio (total consolidated senior secured indebtedness, less the aggregate amount of certain unrestricted cash and unrestricted permitted investments, as defined, over consolidated EBITDA, as defined) and a minimum interest expense coverage ratio (consolidated EBITDA, as defined, over the sum of consolidated cash interest expense, as defined, and preferred dividends, as defined). Our permitted total net leverage ratio under the Credit Agreement is 4.00 to 1.00 as of September 30, 2021. If we were to complete an acquisition which qualifies for a Covenant Holiday Period, as defined in our Credit Agreement, then our permitted total net leverage ratio cannot exceed 4.50 to 1.00 during that period. Our actual total net leverage ratio was 1.65 to 1.00 at September 30, 2021. Our permitted interest expense coverage ratio under the Credit Agreement is 3.00 to 1.00 as of September 30, 2021. Our actual interest expense coverage ratio was 12.94 to 1.00 at September 30, 2021. At September 30, 2021, we were in compliance with our financial covenants.

The following is a reconciliation of net income, as reported, which is a GAAP measure of our operating results, to Consolidated Bank EBITDA, as defined in our Credit Agreement, for the twelve months ended September 30, 2021 (dollars in thousands). We present Consolidated Bank EBITDA to show our performance under our financial covenants.

|  | Twelve Months Ended September 30, 2021 |
| --- | ---: |
| Net income | $68,180 |
| Bank stipulated adjustments: |  |
| Interest expense | 14,510 |
| Income tax expense | 1,980 |
| Depreciation and amortization | 52,500 |
| Non-cash compensation expense(1) | 9,880 |
| Non-cash charges for deferred tax asset valuation allowances | 250 |
| Other non-cash expenses or losses | 1,880 |
| Non-recurring expenses or costs(2) | 14,890 |
| Extraordinary, non-recurring or unusual gains or losses | 1,470 |
| Effects of purchase accounting adjustments | 830 |
| Business and asset dispositions | 450 |
| Net losses on early extinguishment of debt | 3,000 |
| Permitted acquisitions | 1,770 |
| Currency gains and losses | 420 |
| Consolidated Bank EBITDA, as defined | $172,010 |

|  | September 30, 2021 |  |
| --- | ---: | --- |
| Total Indebtedness, as defined | $284,200 |  |
| Consolidated Bank EBITDA, as defined | 172,010 |  |
| Total net leverage ratio | 1.65 | x |
| Covenant requirement | 4.00 | x |

|  | Twelve Months Ended September 30, 2021 |
| --- | ---: |
| Interest expense | $14,510 |
| Bank stipulated adjustments: |  |
| Interest income | (190) |
| Non-cash amounts attributable to amortization of financing costs | (1,030) |
| Total Consolidated Cash Interest Expense, as defined | $13,290 |

41

|  | September 30, 2021 |  |
| --- | ---: | --- |
| Consolidated Bank EBITDA, as defined | $172,010 |  |
| Total Consolidated Cash Interest Expense, as defined | 13,290 |  |
| Actual interest expense coverage ratio | 12.94 | x |
| Covenant requirement | 3.00 | x |

(1) Non-cash compensation expenses resulting from the grant of equity awards.

(2) Non-recurring costs and expenses relating to diligence and transaction costs, purchase accounting costs, severance, relocation, restructuring and curtailment expenses.

Our revolving credit facility allows for the issuance of letters of credit, not to exceed $40.0 million in aggregate. We placed restricted cash on deposit with a financial institution to be held as cash collateral for our outstanding letters of credit; therefore, as of September 30, 2021 and December 31, 2020, we had no letters of credit issued against our revolving credit facility. At September 30, 2021, we had no amounts outstanding under our revolving credit facility and had approximately $300.0 million available after giving effect to letters of credit issued and outstanding. At December 31, 2020, we had $50.5 million outstanding under our revolving credit facility and had approximately $249.5 million available after giving effect to letters of credit issued and outstanding. Our letters of credit, or corresponding restricted cash deposits, are used for a variety of purposes, including support of certain operating lease agreements, vendor payment terms and other subsidiary operating activities, and to meet various states' requirements to self-insure workers' compensation claims, including incurred but not reported claims. Our borrowing capacity was not reduced by leverage restrictions contained in the Credit Agreement as of September 30, 2021 and December 31, 2020.

We rely upon our cash flow from operations and available liquidity under our revolving credit facility to fund our debt service obligations and other contractual commitments, working capital and capital expenditure requirements. At the end of each quarter, we have historically used cash on hand from our domestic and foreign subsidiaries to pay down amounts outstanding under our revolving credit facility, as applicable.

Our weighted average borrowings during the first nine months of 2021 approximated $402.5 million, compared to approximately $387.7 million during the first nine months of 2020, primarily due to a higher aggregate principal balance on our senior notes due to the issuance of the 2029 Senior Notes and the redemption of the 2025 Senior Notes during the first half of 2021.

In May 2021, we, through one of our non-U.S. subsidiaries, entered into a revolving loan facility with a borrowing capacity of $4 million. The facility is guaranteed by TriMas Corporation. There were no borrowings on this loan facility as of September 30, 2021.

Cash management related to our revolving credit facility is centralized. We monitor our cash position and available liquidity on a daily basis and forecast our cash needs on a weekly basis within the current quarter and on a monthly basis outside the current quarter over the remainder of the year. Our business and related cash forecasts are updated monthly.

In considering the economic uncertainty surrounding the potential business impacts from the COVID-19 pandemic with respect to our operations, supply chains, distribution channels, and end-market customers, we have taken certain defensive actions as we monitor our cash position and available liquidity. These actions have included suspending our repurchase of our common stock, borrowing on our revolving credit facility, tightening our capital expenditures, advanced monitoring of our accounts receivable balances and flexing cost structures of operations expected to be most impacted by COVID-19. Given strong cash generation and our current liquidity position, we have subsequently relaxed certain of these actions, choosing to further invest in capital expenditures for our businesses and resume purchasing shares of our common stock.

The majority of our cash on hand as of September 30, 2021 is located within the U.S., and given available funding under our revolving credit facility of $300.0 million at September 30, 2021 (after consideration of the aforementioned leverage restrictions) and based on forecasted cash sources and requirements inherent in our business plans, we believe that our liquidity and capital resources, including anticipated cash flows from operations, will be sufficient to meet our debt service, capital expenditure and other short-term and long-term obligations for the foreseeable future, as well as dividends and share repurchases.

We are subject to variable interest rates on our revolving credit facility. At September 30, 2021, 1-Month LIBOR approximated 0.08%. At September 30, 2021, we had no amounts outstanding on our revolving credit facility and, therefore, no variable rate-based borrowings outstanding.

In addition to our long-term debt, we have other cash commitments related to leases. We account for these lease transactions as operating leases, and annual rent expense for continuing operations related thereto approximated $9.4 million in 2020. We expect leasing will continue to be an available financing option to fund future capital expenditure requirements.

In March 2020, we announced our Board of Directors had authorized us to increase the purchase of our common stock up to $250 million in the aggregate, an increase of $100 million from the prior authorization. In the three and nine months ended September 30, 2021, we purchased 129,866 and 570,084 shares of our outstanding common stock for an aggregate purchase price of approximately $4.0 million and $18.2 million, respectively. Since the initial authorization through September 30, 2021, we have purchased 3,824,815 shares of our outstanding common stock for an aggregate purchase price of approximately $106.5 million. We will continue to evaluate opportunities to return capital to shareholders through the purchase of our common stock and the payment of dividends, depending on market conditions, including the potential impact of the COVID-19 pandemic, and other factors.

### Market Risk

We conduct business in various locations throughout the world and are subject to market risk due to changes in the value of foreign currencies. The functional currencies of our foreign subsidiaries are primarily the local currency in the country of domicile. We manage these operating activities at the local level and revenues and costs are generally denominated in local currencies; however, results of operations and assets and liabilities reported in U.S. dollars will fluctuate with changes in exchange rates between such local currencies and the U.S. dollar.

We use derivative financial instruments to manage currency risks associated with our procurement activities denominated in currencies other than the functional currency of our subsidiaries and the impact of currency rate volatility on our earnings. As of September 30, 2021, we were party to foreign exchange forward and swap contracts to hedge changes in foreign currency exchange rates with notional amounts of approximately $126.9 million. We also use cross-currency swap agreements to mitigate currency risks associated with the net investment in certain of our foreign subsidiaries. See Note 10, "*Derivative Instruments*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q for additional information.

We are also subject to interest risk as it relates to our long-term debt. See Note 9, "*Long-term Debt*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q for additional information.

### Common Stock

TriMas is listed in the NASDAQ Global Select Market. Our stock trades under the symbol "TRS."

### Credit Rating

We and certain of our outstanding debt obligations are rated by Standard & Poor's and Moody's. On March 24, 2021, Moody's assigned a Ba3 rating to our 2029 Senior Notes. See Note 9, *"Long-term Debt"* included in Part I, Item 1, *"Notes to Unaudited Consolidated Financial Statements"* within this quarterly report on Form 10-Q. Moody's also affirmed a Ba2 Corporate Family Rating and maintained its outlook as stable. On March 15, 2021, Standard & Poor's assigned a BB- rating to our 2029 Senior Notes. On February 26, 2021, Standard & Poor's affirmed a BB corporate credit rating and maintained its outlook as stable. If our credit ratings were to decline, our ability to access certain financial markets may become limited, our cost of borrowings may increase, the perception of us in the view of our customers, suppliers and security holders may worsen and as a result, we may be adversely affected.

### Outlook

It has now been more than one year since the onset of the COVID-19 pandemic. The COVID-19 pandemic has significantly affected each of our businesses and how we operate, albeit in different ways and magnitudes. Sales in our Packaging segment for dispensing and closure products we supply that are used in applications to fight the spread of germs continue to be much stronger than before the COVID-19 pandemic, although, as expected, have abated from peak levels in 2020 at the onset of the COVID-19 pandemic. Sales in our Specialty Products segment had been depressed by low levels of industrial activity in the U.S., but have begun to rebound in second and third quarters of 2021. Sales in our Aerospace segment are expected to be lower than historical levels for an indefinite period as a result of low new commercial aircraft builds, but have been boosted by customers' stocking orders during the first nine months of 2021.

We believe our financial results demonstrate our ability to effectively leverage our TriMas Business Model, working across our businesses with a high degree of connectivity to respond to changing market conditions, including the ongoing challenges presented by the COVID-19 pandemic. We have capitalized on opportunities where market demand was high, while also taking swift actions where market demand was sharply reduced. We have continued to take proactive realignment actions to mitigate the effects of lower demand from the COVID-19 pandemic as much as practical.

While we experienced increased sales levels during third quarter 2021, as compared to the same period in 2020, we believe there will be a continued period of uncertainty related to demand levels for our products, whether it be when new aircraft builds will ramp-up that require our fasteners or engineered products or whether industrial demand will continue to improve toward pre-pandemic levels. We expect to continue to mitigate, as much as practical, the impact of low volumes in the most challenged end markets, executing realignment actions as necessary so we are positioned to gain operating leverage when these end markets recover. We believe we remain well positioned to capitalize on the recovery of the aerospace and industrial markets, as well as available market growth opportunities. We believe the continued effectiveness of vaccines, as well as continued measures intended to control the spread of the virus and future variants thereof, are among the most significant factors that could impact demand for our products.

As a result of continued uncertainties resulting from the COVID-19 pandemic, and their potential impact to our future results of operations, as well as to TriMas' market capitalization, we may record additional cash and non-cash charges related to further realignment actions, as well for uncollectible customer account balances, excess inventory and idle production equipment. At this time, we are not able to estimate the extent or amount of any such potential cash and non-cash charges.

Following the issuance of our 2029 Senior Notes and the amendment of our Credit Agreement in 2021, we believe our capital structure remains strong and that we have sufficient headroom under our financial covenants, and ample cash and available liquidity under our revolving credit facility, to meet our debt service, capital expenditure and other short-term and long-term obligations for the foreseeable future, as well as dividends and share repurchases.

We expect to continue to leverage the tenets of our TriMas Business Model to manage our multi-industry businesses and address the ongoing challenges presented by the COVID-19 pandemic, and on a longer-term basis, achieve our growth plans, execute continuous improvement initiatives to offset inflationary pressures, and seek lower-cost sources for input costs, all while continuously assessing the appropriateness of our manufacturing footprint and fixed-cost structure.

### Impact of New Accounting Standards

See Note 2, "*New Accounting Pronouncements*," included in Part 1, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," within this quarterly report on Form 10-Q.

### Critical Accounting Policies

Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions used in calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, our evaluation of business and macroeconomic trends, and information from other outside sources, as appropriate.

During the quarter ended September 30, 2021, there were no material changes to the items that we disclosed as our critical accounting policies in Part II, Item 7, "*Management's Discussion and Analysis of Financial Condition and Results of Operations*," in the Annual Report on Form 10-K for the year ended December 31, 2020.

## Market risk

As filed, 649 characters.

In the normal course of business, we are exposed to market risk associated with fluctuations in foreign currency exchange rates. We are also subject to interest risk as it relates to long-term debt. See Part I, Item 2, "*Management's Discussion and Analysis of Financial Condition and Results of Operations,*" for details about our primary market risks, and the objectives and strategies used to manage these risks. Also see Note 9, "*Long-term Debt*," and Note 10, "*Derivative Instruments*," in Part I, Item 1, "*Notes to Unaudited Consolidated Financial Statements*," included within this quarterly report on Form 10-Q for additional information.

## Controls and procedures

As filed, 2,097 characters.

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

### Evaluation of disclosure controls and procedures

As of September 30, 2021, an evaluation was carried out by management, with the participation of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) pursuant to Rule 13a-15 of the Exchange Act. The Company's disclosure controls and procedures are designed only to provide reasonable assurance that they will meet their objectives. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of September 30, 2021, the Company's disclosure controls and procedures are effective to provide reasonable assurance that they would meet their objectives.

### Changes in internal control over financial reporting

In response to the COVID-19 pandemic, we have required certain employees, some of whom are involved in the operation of our internal controls over financial reporting, to work from home. Despite this change, there have been no changes in the Company's internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. We are continually monitoring and assessing the COVID-19 pandemic on our internal controls to minimize any impact it may have on their design and operating effectiveness.

## Risk factors

As filed, 388 characters.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part 1, Item 1A., "*Risk Factors*," in our 2020 Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. There have been no significant changes in our risk factors as disclosed in our 2020 Annual Report on Form 10-K.

Filed Oct 28, 2021.
Source: SEC EDGAR, the filing index for accession 0000842633-21-000085. Last ingested by Listed: Nov 15, 2026, 01:26 ET. No prices; not investment advice.
